loading
Schlusskurs vom Vortag:
$2.35
Offen:
$2.34
24-Stunden-Volumen:
290.23K
Relative Volume:
0.07
Marktkapitalisierung:
$130.55M
Einnahmen:
$76.19M
Nettoeinkommen (Verlust:
$-1.61M
KGV:
233.50
EPS:
0.01
Netto-Cashflow:
$28.98M
1W Leistung:
-1.48%
1M Leistung:
-19.48%
6M Leistung:
+169.10%
1J Leistung:
+65.02%
1-Tages-Spanne:
Value
$2.32
$2.4025
1-Wochen-Bereich:
Value
$2.30
$2.45
52-Wochen-Spanne:
Value
$0.5052
$3.22

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name
Firmenname
Spero Therapeutics Inc
Name
Telefon
857-242-1600
Name
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Name
Mitarbeiter
32
Name
Twitter
@spero_tx
Name
Nächster Verdiensttermin
2025-03-19
Name
Neueste SEC-Einreichungen
Name
SPRO's Discussions on Twitter

Vergleichen Sie SPRO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
SPRO
Spero Therapeutics Inc
2.335 133.07M 76.19M -1.61M 28.98M 0.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.90 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
566.75 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.21 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
592.45 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.75 31.91B 3.81B -644.79M -669.77M -6.24

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Herabstufung Evercore ISI Outperform → In-line
2022-09-23 Hochstufung Evercore ISI In-line → Outperform
2021-10-01 Herabstufung Oppenheimer Outperform → Perform
2021-01-22 Bestätigt H.C. Wainwright Buy
2020-12-16 Eingeleitet Berenberg Buy
2020-09-29 Eingeleitet Evercore ISI Outperform
2019-11-05 Bestätigt H.C. Wainwright Buy
2019-09-09 Eingeleitet Janney Buy
2018-02-09 Eingeleitet Cantor Fitzgerald Overweight
2017-11-27 Eingeleitet BofA/Merrill Neutral
2017-11-27 Eingeleitet Oppenheimer Outperform
2017-11-27 Eingeleitet Stifel Buy
Alle ansehen

Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten

pulisher
09:10 AM

Is Spero Therapeutics Inc. a good long term investmentExceptional market positioning - PrintWeekIndia

09:10 AM
pulisher
08:35 AM

What drives Spero Therapeutics Inc. stock priceTriple-digit growth rates - Autocar Professional

08:35 AM
pulisher
Jul 24, 2025

What analysts say about Spero Therapeutics Inc. stockSuperior portfolio returns - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

What institutions are buying Spero Therapeutics Inc. stock nowBreakneck growth rates - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

What risks could impact Spero Therapeutics Inc. stock performanceOutstanding stock performance - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Why Spero Therapeutics Inc. stock is on top investor watchlistsOutstanding capital appreciation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 22, 2025

Spero Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Will Spero Therapeutics Inc. stock benefit from AI tech trendsTrend Based Entry Alerts - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

When is the best time to buy Spero Therapeutics Inc. stockFree Real-Time Trading Opportunities - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price - simplywall.st

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Spero Therapeutics Inc. stock price move sharplyMarket Timing Advice - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Spero Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Spero Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser

Jul 15, 2025
pulisher
Jul 01, 2025

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above Fifty Day Moving Average – What’s Next? - Defense World

Jul 01, 2025
pulisher
Jun 28, 2025

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership - Yahoo

Jun 28, 2025
pulisher
Jun 25, 2025

Is Spero Therapeutics, Inc. overvalued or undervalued? - MarketsMojo

Jun 25, 2025
pulisher
Jun 17, 2025

Complicated Urinary Tract Infection Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025
pulisher
Jun 12, 2025

SPRO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

Spero TherapeuticsAdditional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Buys Shares of 55,051 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Jane Street Group LLC Takes Position in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Spero Therapeutics Inc (SPRO) Is A Good Stock To Invest In - Stocksregister

Jun 06, 2025
pulisher
Jun 06, 2025

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled - MSN

Jun 06, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 25,050 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Jun 04, 2025
pulisher
May 31, 2025

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week - Insider Monkey

May 31, 2025
pulisher
May 31, 2025

Spero Therapeutics stock hits 52-week high at $2.53 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 31, 2025

Complicated Urinary Tract Infection Oral Antibiotic Approaches Approval - Vax-Before-Travel

May 31, 2025
pulisher
May 30, 2025

Spero Therapeutics stock hits 52-week high at $2.53 - Investing.com India

May 30, 2025
pulisher
May 30, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - MSN

May 30, 2025

Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Spero Therapeutics Inc-Aktie (SPRO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Rajavelu Esther
CFO & CBO
Feb 05 '25
Sale
0.78
20,689
16,137
724,720
Shukla Sath
CEO & President
Feb 05 '25
Sale
0.78
155,333
121,160
1,736,883
Mahadevia Ankit
Director
Feb 05 '25
Sale
0.78
69,219
53,991
689,866
Rajavelu Esther
CFO & CBO
Nov 07 '24
Sale
1.31
23,351
30,590
396,515
Rajavelu Esther
CFO & CBO
Nov 08 '24
Sale
1.30
17,245
22,418
379,270
Mahadevia Ankit
Director
Aug 27 '24
Sale
1.35
5,912
7,981
759,085
Keutzer Timothy
Chief Operating Officer
Aug 27 '24
Sale
1.35
2,213
2,988
531,837
Shukla Sath
CEO & President
Aug 27 '24
Sale
1.35
2,757
3,722
1,140,809
Shukla Sath
CEO and President
Aug 05 '24
Sale
1.31
17,641
23,110
1,143,566
Shukla Sath
CEO and President
Aug 02 '24
Sale
1.32
14,800
19,536
1,161,207
$23.29
price down icon 1.74%
$36.50
price up icon 0.00%
$103.56
price down icon 0.03%
$27.38
price down icon 0.69%
$113.86
price down icon 0.68%
biotechnology ONC
$288.37
price down icon 2.39%
Kapitalisierung:     |  Volumen (24h):